ImmunityBio's shares climbed 41.36% on February 18, 2026, after the European Commission granted conditional marketing authorization for ANKTIVA, the company's immunotherapy treatment for bladder cancer. The approval represents a significant regulatory milestone, enabling the company to commercialize the drug across more than 30 European nations and expand its addressable market substantially.
The conditional authorization marks a critical step in ANKTIVA's commercialization trajectory, as it allows ImmunityBio to begin generating revenue from European sales while completing additional post-authorization studies required under the conditional approval framework. This regulatory pathway, designed for therapies addressing unmet medical needs, typically expedites patient access to promising treatments while maintaining safety oversight.
Analysts noted that while the approval provides meaningful near-term revenue potential, ImmunityBio's valuation remains contingent upon ANKTIVA's commercial execution and clinical performance in the European market. The company now faces the operational challenge of establishing distribution networks, managing manufacturing scale-up, and meeting revenue expectations that have likely been incorporated into current market valuations.